VolitionRx (NYSE:VNRX) Shares Up 24.2% – Time to Buy?

VolitionRx Limited (NYSE:VNRX) shares traded up 24.2% during mid-day trading on Thursday . The stock traded as high as $0.3863 and last traded at $0.3548. 14,913,866 shares changed hands during trading, an increase of 293% from the average session volume of 3,797,115 shares. The stock had previously closed at $0.2857.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on VNRX. HC Wainwright reduced their price target on shares of VolitionRx from $2.50 to $1.50 and set a “buy” rating on the stock in a research report on Monday, November 17th. Maxim Group downgraded shares of VolitionRx from a “buy” rating to a “hold” rating in a report on Wednesday, December 3rd. Finally, D. Boral Capital reissued a “buy” rating and set a $3.00 price objective on shares of VolitionRx in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $2.50.

VolitionRx Price Performance

The firm has a market cap of $40.89 million, a PE ratio of -0.92 and a beta of 1.23. The company has a 50-day simple moving average of $0.31 and a 200-day simple moving average of $0.52.

Insider Buying and Selling at VolitionRx

In related news, CEO Cameron John Reynolds purchased 110,000 shares of the business’s stock in a transaction dated Tuesday, October 14th. The shares were purchased at an average cost of $0.51 per share, for a total transaction of $56,100.00. Following the completion of the acquisition, the chief executive officer owned 2,534,847 shares in the company, valued at approximately $1,292,771.97. This trade represents a 4.54% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Guy Archibald Innes purchased 96,153 shares of VolitionRx stock in a transaction that occurred on Tuesday, October 14th. The stock was bought at an average cost of $0.51 per share, for a total transaction of $49,038.03. Following the purchase, the director directly owned 1,062,967 shares in the company, valued at $542,113.17. This trade represents a 9.95% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 274,229 shares of company stock worth $136,657 in the last ninety days. 10.40% of the stock is currently owned by corporate insiders.

Institutional Trading of VolitionRx

Institutional investors and hedge funds have recently made changes to their positions in the company. Lagoda Investment Management L.P. increased its position in VolitionRx by 6.7% during the 3rd quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the company’s stock valued at $8,476,000 after purchasing an additional 782,000 shares during the period. Armistice Capital LLC boosted its stake in shares of VolitionRx by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the company’s stock valued at $6,367,000 after purchasing an additional 887,351 shares in the last quarter. Citadel Advisors LLC increased its holdings in VolitionRx by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock valued at $224,000 after buying an additional 135,775 shares during the period. Silverberg Bernstein Capital Management LLC raised its stake in VolitionRx by 15.6% in the third quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the company’s stock worth $157,000 after buying an additional 31,300 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. purchased a new stake in VolitionRx during the second quarter worth $52,000. 8.09% of the stock is currently owned by institutional investors.

About VolitionRx

VolitionRx NV is a multi-national in vitro diagnostics company focused on the development and commercialization of novel blood-based tests for the detection and monitoring of cancer and other diseases. The company’s proprietary Nucleosomics® technology leverages epigenetic and structural changes in nucleosomes—fragments of DNA wrapped around histone proteins—to identify disease-specific biomarkers in blood samples. VolitionRx’s primary goal is to offer simple, minimally invasive tests that facilitate early detection and improve patient outcomes.

VolitionRx’s product pipeline centers on the Nu.Q® family of immunoassays, which are designed to measure concentrations and modifications of circulating nucleosomes.